Vor Biopharma posts new corporate presentation

Rhea-AI Filing Summary

FAQ

Q: What exhibits are included with this Vor Biopharma 8-K?

8-K Event Classification

What did Vor Biopharma Inc. (VOR) report in this 8-K?

How is the Vor Biopharma (VOR) corporate presentation treated under securities laws?

Where can investors access Vor Biopharma’s latest corporate presentation?

Will the Vor Biopharma (VOR) presentation be automatically incorporated into other SEC filings?

What exhibits are included with this Vor Biopharma 8-K?

The report lists Exhibit 99.1, a corporate presentation dated September 2025, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.

Vor Biopharma Inc. furnished a new corporate presentation to the investment community, dated September 2025, and made it available on its website.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Vor Biopharma Inc. furnished a new corporate presentation to the investment community, dated September 2025, and made it available on its website. The materials are provided under Item 7.01 of a current report and are attached as Exhibit 99.1. The company notes that this information, including Exhibit 99.1, is being furnished rather than filed under the securities laws and will only be incorporated into other filings if specifically referenced.

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Vor Biopharma Inc. reported that it has furnished a new corporate presentation to the investment community, attached as Exhibit 99.1 and dated September 2025.

The corporate presentation furnished under Item 7.01, including Exhibit 99.1, is expressly stated as being furnished and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Vor Biopharma states that a copy of its most recent corporate presentation is available on the Company’s website and is also attached to the report as Exhibit 99.1.

No. Vor Biopharma explains that the information under Item 7.01, including Exhibit 99.1, will not be incorporated by reference into other filings unless expressly set forth by specific reference.

Date: September 2, 2025

Vor Biopharma Inc.

/s/ Jean-Paul Kress

Jean-Paul Kress

Chief Executive Officer

The report lists Exhibit 99.1, a corporate presentation dated September 2025, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 09/02/2025 - 10:43 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 2, 2025

Vor Biopharma Inc.

(Exact name of registrant as specified in its Charter)

Delaware

001-39979

81-1591163

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


500 Boylston Street
Suite 1350
Boston, Massachusetts		02116
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 655-6580

P.O. Box 380121

Cambridge, Massachusetts 02238

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share

VOR

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

Vor Biopharma Inc. (the “Company”) from time to time presents and/or distributes to the investment community presentations related to its business. A copy of its most recent presentation is available on the Company’s website and is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description

99.1		Corporate Presentation, dated September 2025.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR